External reports (aggregated public sources), Value Investors Club

Value Investors Club

External reports (aggregated public sources)

Equity Bottom-Up

<ul><li>TherapeuticsMD has shifted to a healthcare royalty model through a licensing agreement with Mayne Pharmaceuticals</li><li>Downside risk is minimized by a minimum payment obligation in the agreement, with potential for significant upside</li><li>Despite near-term uncertainties, the company has access to additional funding and presents a compelling investment opportunity at its current stock price.</li></ul><p><em>This content is sourced through publicly available sources and has been machine generated. Information displayed is for general informational purposes only. This article was originally published 3 months ago on Value Investors Club.</em></p>

TherapeuticsMD has shifted to a healthcare royalty model through a licensing agreement with Mayne PharmaceuticalsDownside risk is minimized by a minimum payment obligation in the agreement, with potential for significant upsideDespite near-term uncertainties, the company has access to additional funding and presents a compelling investment opportunity at its current stock price.This content is sourced through publicly available sources and has been machine generated. Information displayed is for general informational purposes only. This article was originally published 3 months ago on Value Investors Club.

Therapeuticsmd, Inc. (TXMD) - Thursday, May 23, 2024

United States

TherapeuticsMD, Inc. is a specialty pharmaceutical company focused on creating safe and effective branded and generic prescription, and over-the-counter products targeted exclusively for women. The Company develops three advanced hormone replacement products designed to alleviate the symptoms of and reduce the health risks resulting from menopause-related hormone deficiencies.

Price Gauge
52-week Range	0.00 - 0.00
Market Cap (USDm)	0.00
P/E	0.00
Dividend (Yield)	0.00

TherapeuticsMD (TXMD US)

Therapeuticsmd, Inc. (TXMD) - Thursday, May 23, 2024

Despite near-term uncertainties, the company has access to additional funding and presents a compelling investment opportunity at its current stock...

Value Investors Club

Price Gauge

52-week Range

Market Cap (USDm)

P/E

Dividend (Yield)